Fuller & Thaler Asset Management Inc. Buys 242,167 Shares of Halozyme Therapeutics, Inc. $HALO

Key Points

• Fuller & Thaler Asset Management Inc. increased its holdings in Halozyme Therapeutics by 27.3%, acquiring 242,167 shares, bringing its total ownership to 1,130,019 shares valued at approximately $72.1 million.
• CEO Helen Torley sold 20,000 shares at an average price of $63.51, resulting in a 2.65% decrease of her ownership in the company while insiders have sold a total of 80,000 shares in the last three months.
• Analysts have mixed views on Halozyme, with target price increases from several firms, including HC Wainwright raising it to $75.00, while the stock has an average target price of $67.11.

Fuller & Thaler Asset Management Inc. boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 27.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,130,019 shares of the biopharmaceutical company's stock after buying an additional 242,167 shares during the quarter. Fuller & Thaler Asset Management Inc. owned 0.92% of Halozyme Therapeutics worth $72,107,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in HALO. Quantbot Technologies LP grew its stake in shares of Halozyme Therapeutics by 16.1% in the first quarter. Quantbot Technologies LP now owns 8,891 shares of the biopharmaceutical company's stock worth $567,000 after acquiring an additional 1,230 shares during the period. Brooklyn Investment Group boosted its holdings in Halozyme Therapeutics by 1,558.1% in the first quarter. Brooklyn Investment Group now owns 713 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 670 shares during the last quarter. Nations Financial Group Inc. IA ADV grew its position in Halozyme Therapeutics by 2.6% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 14,429 shares of the biopharmaceutical company's stock worth $921,000 after purchasing an additional 367 shares during the period. American Century Companies Inc. raised its stake in Halozyme Therapeutics by 3.4% during the 1st quarter. American Century Companies Inc. now owns 895,412 shares of the biopharmaceutical company's stock valued at $57,136,000 after buying an additional 29,046 shares during the last quarter. Finally, Brandywine Global Investment Management LLC purchased a new stake in Halozyme Therapeutics during the 1st quarter valued at $4,757,000. Hedge funds and other institutional investors own 97.79% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on HALO. JMP Securities raised their price target on Halozyme Therapeutics from $78.00 to $91.00 and gave the stock a "market outperform" rating in a research note on Wednesday, August 6th. JPMorgan Chase & Co. increased their target price on Halozyme Therapeutics from $60.00 to $63.00 and gave the company a "neutral" rating in a report on Thursday, August 7th. Morgan Stanley boosted their price target on Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a research note on Monday. Benchmark cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Finally, Leerink Partners downgraded shares of Halozyme Therapeutics from a "market perform" rating to an "underperform" rating and set a $47.00 price objective on the stock. in a report on Tuesday, May 13th. Four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $67.11.

Insider Transactions at Halozyme Therapeutics

In other Halozyme Therapeutics news, CEO Helen Torley sold 20,000 shares of the firm's stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the sale, the chief executive officer directly owned 733,719 shares of the company's stock, valued at $46,598,493.69. This trade represents a 2.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last ninety days, insiders sold 80,000 shares of company stock valued at $4,532,600. Corporate insiders own 2.40% of the company's stock.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock traded up $0.48 during midday trading on Thursday, hitting $71.61. The stock had a trading volume of 1,863,714 shares, compared to its average volume of 2,029,159. Halozyme Therapeutics, Inc. has a 52-week low of $42.01 and a 52-week high of $72.33. The company has a market capitalization of $8.38 billion, a PE ratio of 16.39, a P/E/G ratio of 0.40 and a beta of 1.17. The firm's fifty day moving average is $58.36 and its two-hundred day moving average is $58.64. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts' consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company's revenue was up 40.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.